Core Viewpoint - Bio-Techne Corporation will host a conference call and webcast to review its fourth quarter and fiscal 2025 financial results on August 6, 2025 [1] Group 1: Conference Call Details - The conference call is scheduled for 8:00 a.m. CDT on August 6, 2025 [1] - Dial-in numbers are provided for both domestic (1-800-274-8461) and international callers (1-203-518-9814) [1] - A recorded rebroadcast will be available from 11:00 a.m. CDT on August 6, 2025, until 11:00 p.m. CDT on September 6, 2025 [2] Group 2: Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [3] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [3] - Bio-Techne's products support scientific investigations into biological processes and aid in drug discovery and clinical testing [3]

Core Insights - Investors in the Medical - Biomedical and Genetics sector may consider Incyte (INCY) and Techne (TECH) for potential value investments [1] Valuation Metrics - Incyte has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Techne has a Zacks Rank of 4 (Sell) [3] - Incyte's forward P/E ratio is 11.80, significantly lower than Techne's forward P/E of 24.67, suggesting that Incyte may be undervalued [5] - Incyte's PEG ratio is 0.47, compared to Techne's PEG ratio of 2.17, indicating better expected earnings growth relative to its valuation [5] - Incyte has a P/B ratio of 3.6, while Techne's P/B ratio is 4.03, further supporting Incyte's valuation attractiveness [6] - Incyte's overall Value grade is A, while Techne's Value grade is C, highlighting Incyte's superior valuation metrics [6] Earnings Outlook - Incyte is noted for its improving earnings outlook, which enhances its attractiveness as a value investment compared to Techne [7]

Core Insights - American Trust Investment Services, Inc. (ATIS) successfully executed the initial public offering (IPO) of K-TECH Solutions Co., Ltd. on Nasdaq, marking a significant achievement in capital markets [1][5] - The IPO involved the offering of 1,600,000 ordinary shares at a price of $4.00 per share, generating gross proceeds of $6.4 million before any discounts and expenses [2] - K-TECH Solutions specializes in educational toys and learning kits, with a diverse product range serving customers in North America, Europe, and other markets [3] Financial Details - The offering generated gross proceeds of $6.4 million, with an additional 240,000 shares available for purchase by the underwriter to cover over-allotments [2] - The net proceeds from the offering will be allocated for product development, production capacity expansion, and general corporate purposes [4] Company Background - ATIS is a leading investment bank providing tailored capital markets solutions for both emerging and established companies, with a strong focus on IPOs and follow-on offerings [6] - The firm is recognized for its hands-on approach and extensive experience in guiding businesses through complex financial transactions [6]

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and ...

Core Insights - Bio-Techne Corporation's Simple Western™ Technology was instrumental in the FDA approval of ZEVASKYN™, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) developed by Abeona Therapeutics [1][5] - ZEVASKYN addresses a significant unmet medical need for RDEB patients, who previously had no durable therapies available [3][8] Company Overview - Bio-Techne Corporation is a global life sciences company that generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [6] - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being its flagship product [8] Technology and Methodology - Simple Western was chosen by Abeona for its speed, reproducibility, sensitivity at picogram levels, and minimal sample volume requirements, effectively detecting both trimeric and monomeric forms of Collagen VII [2][4] - The platform provided GMP-compliant data to ensure consistency across ZEVASKYN product lots, overcoming challenges in analytical standardization and complex assay development [4] Clinical Significance - RDEB is a rare genetic skin disorder caused by mutations in the COL7A1 gene, leading to severe symptoms and increased risk of life-threatening complications [3] - The approval of ZEVASKYN marks a significant milestone in the field of cell-based gene therapy, providing a new treatment option for RDEB patients [5]

Company Overview - Bio-Techne Corp. (TECH) has entered into a distribution agreement with the U.S. Pharmacopeia (USP) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards alongside its analytical solutions, including the Maurice system, to support global monoclonal antibody and gene therapy development [1][8] - The company has a market capitalization of $8.13 billion and an earnings yield of 3.6%, which is significantly better than the industry's -28.4% yield [4] Recent Developments - The partnership with USP is seen as a significant milestone in advancing Bio-Techne's efforts to provide innovative tools and solutions to the scientific community [2] - Bio-Techne's tools enable efficient and integrated analysis of complex biologics from development to product release, addressing analytical challenges in mAb and gene therapy development [8][6] Market Context - The global monoclonal antibody therapeutics market was valued at $222.6 billion in 2023 and is expected to grow at a compound annual growth rate of 14.5% through 2029, driven by advancements in biotechnology and genetic engineering [10] - The need for consistent mAb quality is increasing as patent protections expire and biosimilar versions become available, necessitating thorough testing of critical quality attributes throughout the development and manufacturing processes [5] Stock Performance - Following the announcement of the partnership, Bio-Techne shares dipped 0.1%, closing at $51.84, but the collaboration is expected to positively influence market sentiment towards TECH stock [3] - Over the past three months, TECH shares have declined 11.6%, while the industry has seen a smaller decline of 2.7% [12]

Core Insights - Bio-Techne Corporation has entered into a distribution agreement with the U.S. Pharmacopeia (USP) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards, enhancing support for mAb and gene therapy development globally [1] - The need for consistent mAb quality is increasingly critical as patent protections expire and biosimilars emerge, necessitating rigorous testing of quality attributes during development and manufacturing [2] - Gene therapy, utilizing recombinant AAV, is rapidly growing but faces challenges such as low yields and high costs; USP reference standards provide benchmarks for analytical testing to ensure product quality [3] - USP mAbs and AAV reference standards can be used with Bio-Techne's analytical instruments, facilitating reliable characterization of complex biologics throughout the development process [4] - The collaboration between Bio-Techne and USP aims to address quality challenges in biotherapeutics, ensuring safety and efficacy for patient care [5] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [6]

Summary of Bio Techne Conference Call Company Overview - **Company**: Bio Techne - **Analyst**: Matt Sykes, Goldman Sachs - **CFO**: Jim Hipple - **Head of IR**: David Claire Key Highlights from Fiscal Q3 Results - **Overall Growth**: Achieved 6% organic growth in Q3 despite macroeconomic headwinds [5][6] - **Protein Sciences Segment**: Notable 7% growth, driven by widespread demand across core reagents and instrument platforms [5][6] - **Large Pharma Market**: Contributed significantly to growth, accounting for 30% of total revenue, with double-digit growth observed [6][7] U.S. Academic Market Insights - **Revenue Contribution**: U.S. academic customers represent approximately 12% of total revenue [12] - **Market Volatility**: Academic market has been volatile due to budget cuts and NIH funding fluctuations, but core reagents remain stable [10][11] - **International Exposure**: Academic markets outside the U.S., particularly in Europe, have shown robust growth, helping to stabilize overall academic revenue [14] Tariff Exposure and Mitigation - **Manufacturing Resilience**: Most products manufactured in the U.S., with core reagents exempt from tariffs, minimizing exposure [16][17] - **Mitigation Strategies**: Ability to ramp up production in non-China facilities to avoid tariff impacts [18] China Market Performance - **Revenue Impact**: China accounts for about 8% of total revenue, with recent quarters showing negative mid-single-digit growth [20][21] - **Customer Sentiment**: A slight shift towards optimism among customers in China, indicating potential for future growth [22][23] Biopharma Market Dynamics - **Market Segmentation**: Distinction between large pharma and biotech, with large pharma showing more stability and less volatility [26][27] - **R&D Budgets**: Anticipated increases in R&D budgets for large pharma in 2025, despite recent caution due to external factors [28][30] Instrumentation and Consumables - **Growth in Instrumentation**: Achieved upper single-digit growth in instrumentation, driven by strong consumable pull-through [43][44] - **Competitive Advantage**: Unique product offerings with minimal direct competition in key instrument platforms [45][46] GMP Reagents and Cell & Gene Therapy - **Revenue Dynamics**: Growth in GMP reagents is lumpy due to reliance on clinical trial purchases, but reflects progress in customer development [50][52] - **Wilson Wolf Acquisition**: Bio Techne owns 20% of Wilson Wolf, with plans to acquire the remaining 80% based on performance metrics, enhancing growth potential in cell therapy [62][65] Spatial Biology and Diagnostics - **Market Position**: Bio Techne is a leading player in spatial biology, with a focus on translational applications and a profitable business model [67][68] - **COMET Platform**: New automated solution for spatial biology, capable of multi-omic detection, enhancing reagent pull-through [69][70] Financial Outlook - **Q4 Expectations**: Anticipating low single-digit growth due to continued market challenges, particularly in large pharma [73][75] - **Margin Projections**: Expected decline in operating margins due to tariff impacts, but viewed as a temporary issue [76][77] Capital Allocation Strategy - **Share Repurchase Plan**: Announced a $500 million share repurchase plan, indicating confidence in company valuation and a tactical approach to capital allocation [78][81] - **M&A Strategy**: Continued focus on M&A as a key growth strategy, particularly targeting private companies [80][82]

Summary of Biotechni Conference Call Industry Overview - The life science tools industry is experiencing significant volatility due to macroeconomic factors and uncertainties, particularly in the U.S. and China [1][3] - The company has observed a recovery in the life science tools space, particularly in the pharmaceutical sector, which has shown double-digit growth across various geographies [3][4] Company Performance - The company reported double-digit growth in the pharmaceutical segment, which is widespread across its portfolio [4] - Academic revenue, which constitutes about 12% of total revenue, has been stable despite discussions of NIH budget cuts [5][6] - The worst-case scenario of a 40% cut in NIH funding would only result in a negative 1% impact on the company's projected growth rate over five years [6][7] Market Dynamics - Smaller biotech firms have been conservative in spending due to external market uncertainties, impacting their growth [9][10] - The pharmaceutical sector has seen a slight deceleration in growth rates from double digits to mid-single digits due to tariff discussions and pricing uncertainties [11][12] Academic Market Insights - Academic sales have remained stable despite concerns over funding cuts, attributed to the psychological impact on purchasing behavior [15][17] - Daily sales in the academic sector have shown stability over the past three months, indicating a return to normalcy [17] Instrumentation and Product Lines - The instrumentation segment, which accounts for about 20% of revenue, has seen growth driven by the biologics platform and specific products like the Maurice instrument [18][19] - The company is well-positioned in the bioprocessing market, with opportunities in biosimilars and other emerging markets [19][20] Tariff Impact and Mitigation Strategies - The company has low exposure to tariffs, with most of its reagents exempt from tariff increases [22][23] - Manufacturing strategies include moving production to Canada and stocking inventories in Europe and Asia to mitigate future tariff impacts [25][26] China Market Dynamics - China represents 88% of the company's revenues, and there are signs of a subtle shift towards optimism in customer demand [27][28] - The company is targeting the replacement of older instruments with newer technology, which is expected to drive growth [30][31] - Despite competition, the company maintains a strong position based on quality and consistency, which are prioritized by customers [34] Long-term Growth Outlook - The company remains bullish on long-term growth in China, driven by an aging population and ongoing scientific innovation [35][36] - The life science tools market is expected to grow significantly, with the company well-positioned to capitalize on these trends [37] Liquid Biopsy Segment - The liquid biopsy business is focused on scaling sustainably, with growth rates exceeding 20% [39] - The company is integrating exosome technology into its kit business, targeting multiple tests for disease monitoring [40][41] Spatial Market Position - The company is differentiating itself in the mid-plex spatial market by offering integrated solutions that combine molecular and antibody reagents [46][48] - The competitive landscape includes key players like Akoya and Molteni, but the company has a high win rate against these competitors [53] Margin Performance - The company achieved nearly 200 basis points of margin improvement year-over-year, although a contraction of approximately 150 basis points is expected in the near term due to tariffs and lower growth rates [54][55] - The long-term target is to achieve operating margins above 35%, supported by organic growth and effective cost management [55]

Summary of Biotechnology Management Presentation Company Overview - **Company Name**: Bio Techne - **Headquarters**: Minneapolis - **Employees**: Approximately 3,100 across 34 global locations - **Industry**: Biotechnology, focusing on protein-based reagents and products Core Business Segments - **Segments**: - Protein Sciences - Diagnostics and Spatial Biology - **Revenue Breakdown (2024)**: - Total Revenue: $1.2 billion - 80% from consumables - 9% from instrumentation - 9% from services related to instrumentation - 2% from royalties - **Revenue Composition**: - 72% from Protein Sciences - 28% from Diagnostics and Spatial Biology, which has grown from 26% the previous year [8][9][10] Growth Factors and Market Trends - **Key Growth Areas**: - Discovery of novel biological insights - Development and manufacturing of advanced therapeutics - Enablement of precision diagnostics - **Market Trends**: - Multiomic insight generation - AI-enabled innovation - Novel therapeutic approaches like cell therapy - Precision medicine and healthy aging [16][18][19] Financial Performance - **Recent Growth**: - 1% growth during a challenging period, with a return to 6% organic growth year-to-date for fiscal year 2025 [34] - **Operating Margins**: - Targeting 35-40% EBITDA range, with a historical CAGR of 40% [34][45] - **Market Position**: - Positioned to outgrow the overall market by 500 to 1,000 basis points [44] Innovations and Product Development - **Recent Launches**: - LEO instrument for high-throughput western blotting - Multi-omic solutions for RNA and protein visualization - ESR1 kit for breast cancer management [26][29][31] - **Acquisitions**: - Focus on M&A to enhance product offerings and market position, particularly in high-margin or high-growth companies [36] Sustainability and Corporate Governance - **Sustainability Initiatives**: - Published fourth corporate sustainability report, focusing on reducing waste and improving environmental footprint [42] - **Diversity and Inclusion**: - Commitment to a diverse and inclusive workplace [43] Conclusion - **Strategic Position**: - Bio Techne has built a differentiated proteomic core portfolio over 48 years, addressing a $28 billion market opportunity with a strong innovation pipeline [44] - **Future Aspirations**: - Aim for sustainable financial performance while unlocking scientific possibilities [45]